TAK
TAKEDA PHARMACEUTICAL CO LTDMarquee-fund ownership over time
This quarter's activity
New positions opened
Positions exited
Current holders
Sorted by tenure (longest first)| Fund | First disclosed | Held | Entry price | Latest close | Return on entry |
|---|---|---|---|---|---|
| Renaissance Technologies | Q3 2024(8Q snapshot) | 7Q | $13 | $17 | +25% |
| Citadel Advisors re-entered | Q3 2024(8Q snapshot) | 7Q | $14 | $17 | +21% |
| AQR Capital Management | Q3 2024(8Q snapshot) | 7Q | $14 | $17 | +21% |
| D.E. Shaw re-entered | Q4 2024(8Q snapshot) | 6Q | $13 | $17 | +25% |
| Two Sigma Investments | Q2 2026(8Q snapshot) | 1Q | $17 | $17 | -0% |
“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.
Past holders
Funds that exited at some point| Fund | Last entry | Exited | Entry → Exit | Return |
|---|---|---|---|---|
| Millennium Management | Q3 2024 | Q2 2026 | → $17 | +22% |
| Point72 Asset Management | Q1 2025 | Q2 2025 | → $14 | +6% |
| Glenview Capital | Q2 2019 | Q1 2022 | — | +0% |
| Maverick Capital | Q1 2019 | Q2 2020 | → $17 | -8% |
Insider activity
Form 4 — officers, directors, 10%+ ownersFiled within two business days of each transaction by anyone with material insider status at TAKEDA PHARMACEUTICAL CO LTD. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.
30d / 90d windows measured from Apr 28, 2026 — the most recent Form 4 on file — not from today.
- Form 40001395064-26-000140Apr 28, 2026
- Form 40001395064-26-000138Apr 28, 2026
- Form 40001395064-26-000136Apr 28, 2026
- Form 40001395064-26-000134Apr 28, 2026
- Form 40001395064-26-000132Apr 28, 2026
- Form 40001395064-26-000130Apr 28, 2026
- Form 40001395064-26-000128Apr 28, 2026
- Form 40001395064-26-000126Apr 28, 2026
- Form 40001395064-26-000124Apr 28, 2026
- Form 40001395064-25-000172Dec 9, 2025
- Form 40001395064-25-000140Sep 19, 2025
- Form 40001395064-24-000008Jan 25, 2024
- Form 40001395064-23-000040May 26, 2023
- Form 40001395064-22-000146Dec 1, 2022
- Form 40001395064-22-000121Jul 6, 2022
Fundamentals
XBRL · TAKEDA PHARMACEUTICAL CO LTDNot enough XBRL history to plot. TAKEDA PHARMACEUTICAL CO LTDhasn't tagged revenue, net income, EPS, or operating cash flow in the SEC us-gaap taxonomy with at least two fiscal-year periods — typical for SPACs / trust vehicles, pre-revenue biotechs, recent IPOs, and foreign filers reporting under IFRS.
Recent SEC filings
10-K · 10-Q · 8-K · 13D/G · proxyThe most recent material filings for TAKEDA PHARMACEUTICAL CO LTD — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.
- 6-KInterim disclosure (foreign)Jun 9, 2026
- 6-KInterim disclosure (foreign)Jun 5, 2026
- 6-KInterim disclosure (foreign)Jun 5, 2026
- 6-KInterim disclosure (foreign)Jun 1, 2026
- 6-KInterim disclosure (foreign)May 26, 2026
- 6-KInterim disclosure (foreign)May 26, 2026
- 6-KInterim disclosure (foreign)May 26, 2026
- 6-KInterim disclosure (foreign)May 26, 2026
- 6-KInterim disclosure (foreign)May 26, 2026
- 6-KInterim disclosure (foreign)May 19, 2026
- 6-KInterim disclosure (foreign)May 13, 2026
- 6-KInterim disclosure (foreign)May 13, 2026
- 6-KInterim disclosure (foreign)Mar 30, 2026
- 6-KInterim disclosure (foreign)Mar 26, 2026
- 6-KInterim disclosure (foreign)Mar 25, 2026
Trade history
Every open→close lifecycle across tracked funds| Fund | Open date | Close date | Open price | Close price / current | Return |
|---|---|---|---|---|---|
| Two Sigma Investments | Q2 2026 | open | $17 | $17 | -0% |
| Citadel Advisors | Q4 2025 | open | $14 | $17 | +16% |
| D.E. Shaw | Q4 2025 | open | $14 | $17 | +16% |
| D.E. Shaw | Q2 2025 | Q3 2025 | $14 | $15 | +6% |
| Citadel Advisors | Q1 2025 | Q3 2025 | $13 | $15 | +12% |
| Point72 Asset Management | Q1 2025 | Q2 2025 | $13 | $14 | +6% |
| D.E. Shaw | Q4 2024 | Q1 2025 | $13 | $13 | -0% |
| Citadel Advisors | Q3 2024 | Q4 2024 | $14 | $13 | -3% |
| AQR Capital Management | Q3 2024 | open | $14 | $17 | +21% |
| Millennium Management | Q3 2024 | Q2 2026 | $14 | $17 | +22% |
| Renaissance Technologies | Q3 2024 | open | $13 | $17 | +25% |
| Glenview Capital | Q2 2019 | Q1 2022 | $0.00 | — | +0% |
| Maverick Capital | Q1 2019 | Q2 2020 | $19 | $17 | -8% |
- Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
- Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
- “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
- Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
- Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.